Supernus Pharmaceuticals Inc., of Rockville, Md., reported that its second quarter 2020 net product sales totaled $124 million, 21% higher than the same period in 2019, driven by higher net product sales of Trokendi XR and antiepileptic drug Oxtellar XR. Net earnings in the second quarter of 2020 were $34.7 million, or $0.65 per diluted share, as compared to $32.7 million, or $0.61 per diluted share, in the same period last year. As of June 30, 2020, the company had $733.5 million in cash, cash equivalents, marketable securities and long-term marketable securities.

No Comments